SUVEN PHARMACEUTICALS LTD.
NSE : SUVENPHARBSE : 543064ISIN
CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse
: Private
BSE657.9011.8 (+1.83 % )
PREV CLOSE (Rs.) 646.10
OPEN PRICE (Rs.) 652.45
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 3939
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE659.70 12.9 (+1.99 % )
PREV CLOSE(Rs.) 646.80
OPEN PRICE (Rs.) 648.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 659.70 (327 )
VOLUME 122136
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 01-Mar-2024 | Suven Pharmaceuticals shines on planning to merge Cohance with itself | <p style="text-align: justify;">Suven Pharmaceuticals is currently trading at Rs. 678.65, up by 47.75 points or 7.57% from its previous closing of Rs. 630.90 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 653.95 and has touched a high and low of Rs. 712.00 and Rs. 646.00 respectively. So far 1659278 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 767.00 on 04-Jan-2024 and a 52 week low of Rs. 375.00 on 05-Apr-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 712.00 and Rs. 625.10 respectively. The current market cap of the company is Rs. 17281.14 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 26.09% and 13.92% respectively.</p><p style="text-align: justify;">Suven Pharmaceuticals has proposed scheme of amalgamation to merge Cohance Lifesciences (Cohance) with itself. This marks a pivotal moment in Suven's journey, underscoring its commitment to scaling, ensuring consistent earnings, fortifying its financial standing, and advancing towards forging leadership in the integrated CDMO space.</p><p style="text-align: justify;">Cohance is a leading CDMO and Merchant API platform with global leadership in select low-mid volume molecules as well as unique capabilities in the form of its antibody drug conjugates (ADC) platform. </p><p style="text-align: justify;">Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.</p><div style="text-align: justify;"><br></div> |
| 29-Feb-2024 | Amalgamation | Scheme of Arrangement Inter alia, have considered and approved a scheme of amalgamation of Cohance Lifesciences Limited (?Transferor Company?) into and with the Company and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and other rules and regulations framed thereunder, SEBI Master Circular dated 20 June 2023 bearing reference number SEBI/HO/CFD/POD- 2/P/CIR/2023/93 and all amendments thereto (?Scheme?). (Transferor Company and Transferee Company collectively referred to as the ?Amalgamating Companies?). Pursuant to the proposed Scheme, equity shares of the Company shall be issued to the shareholders of the Transferor Company in accordance with the Share Exchange Ratio (as defined below), which would be listed on the BSE Limited and the National Stock Exchange of India Limited (collectively referred to as ?Stock Exchanges?). The Scheme is subject to the receipt of applicable approvals, including approvals from the respective jurisdictional Hon?ble National Company Law Tribunal, SEBI, Department of Pharmaceuticals (if such approval is required pursuant to applicable laws), Stock Exchanges and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary. The Appointed Date for the Scheme shall be the Effective Date (as defined below in this paragraph), or such other date as may be approved by the board of directors of the Amalgamating Companies. Further, the effective date for the Scheme shall be the opening business hours of the first day of the month immediately succeeding the month in which the last of the conditions to the effectiveness of the Scheme, as set out in the Scheme are fulfilled, obtained or otherwise duly waived (?Effective Date?). Further, in connection with the proposed amalgamation contemplated under the Scheme (?Proposed Amalgamation?), the promoter of the Transferor Company (i.e., Jusmiral Holdings Limited) has also agreed to indemnify the Transferee Company with respect to certain matters. |
| 29-Feb-2024 | Scheme of Arrangement | Scheme of Arrangement Inter alia, have considered and approved a scheme of amalgamation of Cohance Lifesciences Limited (?Transferor Company?) into and with the Company and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and other rules and regulations framed thereunder, SEBI Master Circular dated 20 June 2023 bearing reference number SEBI/HO/CFD/POD- 2/P/CIR/2023/93 and all amendments thereto (?Scheme?). (Transferor Company and Transferee Company collectively referred to as the ?Amalgamating Companies?). Pursuant to the proposed Scheme, equity shares of the Company shall be issued to the shareholders of the Transferor Company in accordance with the Share Exchange Ratio (as defined below), which would be listed on the BSE Limited and the National Stock Exchange of India Limited (collectively referred to as ?Stock Exchanges?). The Scheme is subject to the receipt of applicable approvals, including approvals from the respective jurisdictional Hon?ble National Company Law Tribunal, SEBI, Department of Pharmaceuticals (if such approval is required pursuant to applicable laws), Stock Exchanges and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary. The Appointed Date for the Scheme shall be the Effective Date (as defined below in this paragraph), or such other date as may be approved by the board of directors of the Amalgamating Companies. Further, the effective date for the Scheme shall be the opening business hours of the first day of the month immediately succeeding the month in which the last of the conditions to the effectiveness of the Scheme, as set out in the Scheme are fulfilled, obtained or otherwise duly waived (?Effective Date?). Further, in connection with the proposed amalgamation contemplated under the Scheme (?Proposed Amalgamation?), the promoter of the Transferor Company (i.e., Jusmiral Holdings Limited) has also agreed to indemnify the Transferee Company with respect to certain matters. |
| 23-Feb-2024 | USFDA completes inspections at Suven Pharmaceuticals' API, Formulations facilities | <p style="text-align: justify;">US Food & Drug Administration (US FDA) has completed Pre-Approval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections at Suven Pharmaceuticals' Active Pharmaceutical Ingredients (API) and Formulations facilities (Unit-3 and Unit-5, respectively) in Pashamylaram, Hyderabad, India. The inspections were conducted from February 12, 2024, to February 23, 2024. No Form 483 has been issued as a result of the inspection.</p><p style="text-align: justify;">Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.</p><div style="text-align: justify;"><br></div> |
| 06-Dec-2023 | Suven Pharmaceuticals informs about disclosure | <p style="text-align: justify;">Suven Pharmaceuticals has informed that the exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for UTI Mutual Fund.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 24-Nov-2023 | Suven Pharmaceuticals informs about investor presentation | <div>Suven Pharmaceuticals has informed that it enclosed Updated Investor Presentation_Q2 FY 2024.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 11-Oct-2023 | Suven Pharmaceuticals informs about letter of offer | <div>Suven Pharmaceuticals has informed that Kotak Mahindra Capital Company (Manager to the Open Offer) has submitted a copy of Letter of Offer for the attention of the public shareholders of Suven Pharmaceuticals (Target Company).</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 03-Oct-2023 | Bhageria Industries, Apollo Micro Systems and Rail Vikas Nigam to see some action today | <p style="text-align: justify;"><span style="font-weight: bold;">Bhageria Industries</span> has received a Letter of Award (LoA) for the execution of turnkey domestic solar Engineering, Procurement and Construction (Solar EPC) works of a ground mounted Solar Power Project with 10 year's comprehensive Operation & Maintenance from Paranjape Autocast, one of the worldwide trusted Company in supplying intricate engineering products and services. Aggregating to a capacity of 4.5 MW (AC)/ 6.0 MWp (DC), this project has a total order value of Rs 27.70 crore (including comprehensive O&M), without taking taxes into account. The project shall be installed at Village Kombhalne, Taluka Akole, Dist. Ahmednagar.</p><p style="text-align: justify;"><span style="font-weight: bold;">Apollo Micro Systems</span>, a leading company in the Indian Defence sector for electronic manufacturing, hardware designing, weapon integration, and platform integration proposes to set up a state-of-the-art defence equipment manufacturing facility in Hardware Park, Hyderabad subject to approval by the Board of Directors of the Company. The company intends to perform Bhumi Pooja for the plant during upcoming Dusshera and plans to complete within nine months. The company has estimated total investment in the upcoming ventures to be around Rs 150 crore.</p><p style="text-align: justify;"><span style="font-weight: bold;">Rail Vikas Nigam</span> has emerged as Lowest Bidder (L1) for Development of Distribution Infrastructure at South Zone of Himachal Pradesh under the Revamped Reforms-based and Results-linked, Distribution Sector Scheme (Loss Reduction Works). The project cost is Rs 1097.68 crore. The order is to be executed within 24 months.</p><p style="text-align: justify;"><span style="font-weight: bold;">Hero MotoCorp</span> is all set to make a marginal revision in the ex-showroom prices of select motorcycles and scooters, effective from October 3, 2023. The price increase will be around 1% and the exact quantum of increase will vary by specific models and markets. The price revision is part of its regular review of product competitiveness and positioning, factoring inflation, margins and market share.</p><p style="text-align: justify;"><span style="font-weight: bold;">Astra Microwave Products</span>' Joint Venture (JV) company -- Astra Rafael Comsys has bagged Rs 96.49 crore worth of order on September 29, 2023 from Indian Air Force for supply of B-KITS, testers and trainer specific A- KITS for SDR sets of MIG-29 upgraded aircraft. The said order is expected to be executed within 12 months.</p><p style="text-align: justify;">Advent International (Advent) has completed its majority acquisition of <span style="font-weight: bold;">Suven Pharmaceuticals</span> (Suven), one of the top contract development and manufacturing organizations (CDMOs) in India. Advent is also announcing the new Board of Directors and management team for Suven Pharma. </p><p style="text-align: justify;"><span style="font-weight: bold;">Godrej Agrovet</span>'s (GAVL) Oil Palm business is planning to set up an Integrated Palm Oil Complex in the state of Telangana. To be set up in the Khammam district, it will consist of a state the of art Crude Palm Oil mill along with the provision of setting up a refinery in the near future. The company will also establish a nursery with a capacity of up to 7 lakh saplings per year in addition to the seed production & research unit. At the complex, GAVL will be setting up first-ever seed garden in India. This seed garden can provide seeds for the planting of around 90,000 acres of area and shall help Telangana state to achieve targets for oil palm plantation. </p> |
| 30-Sep-2023 | Advent International completes acquisition of Suven Pharmaceuticals | <p style="text-align: justify;">Advent International (Advent) has completed its majority acquisition of Suven Pharmaceuticals (Suven), one of the top contract development and manufacturing organizations (CDMOs) in India. Advent is also announcing the new Board of Directors and management team for Suven Pharma. </p><p style="text-align: justify;">Advent acquired 50.1% stake in Suven at an agreed price of Rs 495/share. An open offer for the remaining 26% of stake will be triggered within stipulated timelines, and the required details will be announced soon. As a majority stakeholder, Advent plans to foster Suven's capabilities to help it strive towards becoming one of the leading companies in the CDMO space globally.</p><p style="text-align: justify;">Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.</p><div style="text-align: justify;"><br></div> |
| 14-Aug-2023 | Suven Pharmaceuticals informs about transcript of conference call | <p style="text-align: justify;">Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Suven Pharmaceuticals has informed that it enclosed the transcript of the earnings conference call for the quarter ended June 30, 2023 conducted after the meeting of Board of Directors held on August 08, 2023. The above information has been uploaded on the Company's website.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
